Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

D. Kerrigan, A. Mantsios, R. Grant, M. Markowitz, P. Defechereux, M. La Mar, S. W. Beckham, P. Hammond, D. Margolis, M. Murray

Research output: Contribution to journalArticlepeer-review

Abstract

Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

Original languageEnglish (US)
Pages (from-to)3540-3549
Number of pages10
JournalAIDS and behavior
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2018

Keywords

  • HIV
  • Long-acting injectable
  • Men
  • PrEP
  • Providers
  • Qualitative
  • Risk behavior

ASJC Scopus subject areas

  • Social Psychology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States'. Together they form a unique fingerprint.

Cite this